Andelyn Biosciences selected to manufacture AAV therapies under CIRM
May 28, 2024
Source: drugdu
106
Andelyn Biosciences, a patient-focused cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), has been selected to manufacture adeno-associated vectors (AAV) therapies using its suspension AAV Curator Platform under the California Institute for Regenerative Medicine (CIRM) Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC).
The CIRM partnership with Andelyn aims to advance BGTC’s mission to develop platforms and standards to propel the development and delivery of customised or ‘bespoke’ gene therapies for millions of people affected with rare diseases. BGTC is focusing on development of cures for eight such diseases, with Andelyn selected to optimise and scale the AAV therapy processes for the treatment of Congenital Hereditary Endothelial Dystrophy – Type 1.
With scalable end-to-end development and manufacturing capabilities across its three Columbus, Ohio facilities, Andelyn aims to work towards the progression of life-altering gene therapies for rare and prevalent diseases.
https://andelynbio.com/news-and-media/andelyn-biosciences-selected-as-viral-vector-manufacturing-partner-for-the-cirm-amp-bgtc/
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Chuangxiang Biotechnology and Ikena Oncology merge to raise $75 million in funding December 25, 2024
- Two biosimilars of pembrolizumab have been approved for marketing, and the second indication of Cononospikinumab has been approved December 25, 2024
- ABB’s maintenance plan based on equipment status helps Jiheng Pharmaceutical December 25, 2024
- CR Group’s Big Move – Integration of Two Major Pharmaceutical Companies Completed December 25, 2024
- CanSino Biologics Launches Phase I/II Clinical Trials for Recombinant Polio Vaccine December 25, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
